Plasma membrane is no barrier to free fatty acid
Our understanding of how long-chain fatty acids cross membranes is changing based on recent work by oratory at Boston University and others. Their research shows that unlike nutrients such as glucose or amino acids, which require a transporter, fatty acids can diffuse spontaneously through protein-free lipid bilayers and cells’ plasma membranes.
A in the Journal of Lipid Research by Anthony Jay and colleagues reveals how molecules previously thought to inhibit fatty acid transport specifically, including sulfosuccinimidyl oleate, or SSO, fit the diffusion model.
Control of fatty acid entry into cells is difficult to visualize. Researchers often have used fatty acid metabolites that become trapped in the cell to infer transport by plasma membrane proteins. The Hamilton lab has focused on distinguishing transmembrane movement from metabolism.
The lab made a that transport of fatty acids across a bilayer can be followed by pH changes. They combined a with phospholipid vesicles enclosing a pH-probe to measure absorption in real time. They showed that natural fatty acids can acquire a proton near the outer leaflet, leading to equilibrium between neutral and ionized forms. The net neutral fatty acid spontaneously diffuses across the bilayer and then releases the proton near the inner leaflet, reducing the internal pH. This energy-free diffusion has been termed the “flip-flop” mechanism.
“Our studies also showed that all fatty acids studied … exhibit rapid flip-flop, and that this mechanism is reversible,” Hamilton said.
The researchers were excited by this finding but acknowledge that it does not exclude a role for proteins. Jay said, “If fatty acids can simply diffuse into cells, how could there be inhibitors of this transmembrane movement?”
The recent paper tests several proposed transport inhibitors, including the gold standard, SSO. Scientists had described SSO as a specific inhibitor of fatty acid entry into cells that acts on the fatty acid transporter CD36 without penetrating membranes. However, Hamilton’s team showed that SSO crosses membranes. Immunofluorescence using novel antibodies that bind SSO-linked fatty acids suggested that SSO modifies numerous proteins on the cell surface and interior, refuting the assumption of CD36 specificity.
The research informs nutritional considerations, Hamilton said. “Metabolism, and not the plasma membrane, controls the retention of fatty acids in cells, by trapping the fatty acids. Although membrane proteins may bind fatty acids or participate in metabolism, they cannot block diffusion in the surrounding bilayer.”
and the fatty acid transport inhibitor sulfosuccinimidyl oleate. The insert on the right suggest that SSO staining is not
exclusive to CD36.
In fact, but CD36 increased the content of intercellular lipids.
For nutrition, Hamilton emphasized, “Healthy fatty acids such as omega 3 fatty acids need to enter cells readily, whereas unhealthy fatty acids, such as trans fatty acids, cannot be excluded from cells and need to be reduced in the diet.”
Hamilton’s lab is moving on to clinical trials using a high concentration of beneficial fatty acids to improve stroke and heart attack outcomes. Meanwhile, he recommends taking omega-3 supplements and eating more nuts.
Another interpretation
According to Maastricht University researchers Jan Glatz and Joost Luiken, the Hamilton lab’s results also could be interpreted as a step toward integration of the argument that fatty acids diffuse across the cell membrane and the view that the protein CD36 is required for fatty acid uptake. In a , Glatz and Luiken lay out their view that CD36 may be helpful but not necessary for lipid uptake.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Bacteriophage protein could make queso fresco safer
Researchers characterized the structure and function of PlyP100, a bacteriophage protein that shows promise as a food-safe antimicrobial for preventing Listeria monocytogenes growth in fresh cheeses.

Building the blueprint to block HIV
Wesley Sundquist will present his work on the HIV capsid and revolutionary drug, Lenacapavir, at the ASBMB Annual Meeting, March 7–10, in Maryland.

Gut microbes hijack cancer pathway in high-fat diets
Researchers at the Feinstein Institutes for Medical Research found that a high-fat diet increases ammonia-producing bacteria in the gut microbiome of mice, which in turn disrupts TGF-β signaling and promotes colorectal cancer.

Mapping fentanyl’s cellular footprint
Using a new imaging method, researchers at State University of New York at Buffalo traced fentanyl’s effects inside brain immune cells, revealing how the drug alters lipid droplets, pointing to new paths for addiction diagnostics.

Designing life’s building blocks with AI
Tanja Kortemme, a professor at the University of California, San Francisco, will discuss her research using computational biology to engineer proteins at the 2026 ASBMB Annual Meeting.

Cholesterol as a novel biomarker for Fragile X syndrome
Researchers in Quebec identified lower levels of a brain cholesterol metabolite, 24-hydroxycholesterol, in patients with fragile X syndrome, a finding that could provide a simple blood-based biomarker for understanding and managing the condition.